Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in Moderate to Severe Chronic Hand Eczema
NCT06283550Phase 2Completed
- Sponsor
- Innovaderm Research
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of abrocitinib in chronic hand eczema (CHE) (3 arms), sponsored by Innovaderm Research. Primary endpoint: modified Total Lesion Symptom Score at 16 weeks. Started May 2024; status: completed.
02
Drugs
abrocitinib
03
Conditions
chronic hand eczema (CHE)
Beyond the preview
Go deeper on NCT06283550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283550.